Home » Stocks » Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. (ZYNE)

Stock Price: $3.88 USD 0.04 (0.91%)
Updated Aug 4, 2020 10:17 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 96.68M
Revenue (ttm) 86,000
Net Income (ttm) -36.13M
Shares Out 24.95M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $3.88
Previous Close $3.84
Change ($) 0.04
Change (%) 0.91%
Day's Open 3.88
Day's Range 3.80 - 3.89
Day's Volume 74,001
52-Week Range 2.55 - 12.51

More Stats

Market Cap 96.68M
Enterprise Value 36.34M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.95M
Float 22.83M
EPS (basic) -1.58
EPS (diluted) -1.57
FCF / Share -1.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.01M
Short Ratio 2.00
Short % of Float 28.14%
Beta 3.09
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,124.23
PB Ratio 1.43
Revenue 86,000
Operating Income -35.65M
Net Income -36.13M
Free Cash Flow -36.54M
Net Cash 60.34M
Net Cash / Share 2.42
Gross Margin n/a
Operating Margin -41,456.75%
Profit Margin n/a
FCF Margin -42,487.53%
ROA -29.32%
ROE -53.85%
ROIC -869.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(158.06% upside)
Current: $3.88
Target: 10.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth----97.4%-65.57%-14.18%-
Gross Profit-0.09-
Operating Income-34.32-40.40-32.82-23.21-12.53-5.67-0.63
Net Income-32.94-39.91-32.01-23.39-12.55-5.67-0.64
Shares Outstanding22.0015.3112.919.074.460.890.49
Earnings Per Share-1.50-2.61-2.48-2.58-2.82-6.44-1.63
Operating Cash Flow-34.82-32.40-25.84-20.44-9.79-3.54-0.12
Capital Expenditures-0.13-0.29-0.12-0.11-0.22-0.02-
Free Cash Flow-34.95-32.68-25.96-20.55-10.00-3.56-0.12
Cash & Equivalents70.0659.7662.5130.9741.519.330.15
Total Debt0.35-----0.50
Net Cash / Debt69.7159.7662.5130.9741.519.33-0.35
Book Value75.6057.6060.9529.5939.71-8.05-4.36
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zynerba Pharmaceuticals, Inc.
Country United States
Employees 28
CEO Armando Anido

Stock Information

Ticker Symbol ZYNE
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ZYNE
IPO Date August 5, 2015


Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.